N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

Sponsor: Centre Hospitalier Metropole Savoie • ClinicalTrials.gov ID: NCT06274268

Registry updated: 2026-10-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

Interventions

  • Sarcopenia diagnostic test (Diagnostic test)
    the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.

Eligibility criteria

Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure

Conditions

Sarcopenia Oncology Physical Inactivity Toxicity Due to Chemotherapy

Locations

  • Centre Hospitalier Metropole Savoie — Chambéry, France
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record